Olema Oncology
Rupa Shetty has extensive experience in the pharmaceutical industry, starting as a Senior Scientist at Ansaris/ Locus Pharmaceuticals in 2001. Rupa then moved on to roles such as Senior Principal Scientist at The Chemistry Research Solution LLC, Contract Research Scientist at Teva Pharmaceuticals, Research Scientist at Prelude Therapeutics, and most recently, Principal Research Scientist at Olema Oncology in 2021. Their work history showcases a progression in roles and responsibilities within the industry.
Rupa Shetty obtained a Doctor of Philosophy (PhD) in Organic Chemistry from the University of Kentucky from 1991 to 1995.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.